Altered hormonal and autonomic nerve responses to hypo- and hyperglycaemia are found in overweight and insulin-resistant individuals and may contribute to the development of type 2 diabetes.


Journal

Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777

Informations de publication

Date de publication:
03 2021
Historique:
received: 16 06 2020
accepted: 01 10 2020
pubmed: 27 11 2020
medline: 16 2 2022
entrez: 26 11 2020
Statut: ppublish

Résumé

Results from animal models and some clinical work suggest a role for the central nervous system (CNS) in glucose regulation and type 2 diabetes pathogenesis by modulation of glucoregulatory hormones and the autonomic nervous system (ANS). The aim of this study was to characterise the neuroendocrine response to various glucose concentrations in overweight and insulin-resistant individuals compared with lean individuals. Overweight/obese (HI, n = 15, BMI ≥27.0 kg/m During hypoglycaemic clamps, there was an elevated cortisol response in HI vs LO (median ΔAUC 12,383 vs 4793 nmol/l × min; p = 0.050) and a significantly elevated adrenocorticotropic hormone (ACTH) response in HI vs LO (median ΔAUC 437.3 vs 162.0 nmol/l × min; p = 0.021). When adjusting for clamp glucose levels, obesity (p = 0.033) and insulin resistance (p = 0.009) were associated with elevated glucagon levels. By contrast, parasympathetic activity was less suppressed in overweight individuals at the last stage of hypoglycaemia compared with euglycaemia (high-frequency power of HRV, p = 0.024). M value was the strongest predictor for the ACTH and P This study supports the hypothesis that altered responses of insulin-antagonistic hormones and the ANS to glucose fluctuations occur in overweight and insulin-resistant individuals, and that these responses are probably partly mediated by the CNS. Their potential role in development of type 2 diabetes needs to be addressed in future research. Graphical abstract.

Identifiants

pubmed: 33241460
doi: 10.1007/s00125-020-05332-z
pii: 10.1007/s00125-020-05332-z
pmc: PMC7864814
doi:

Substances chimiques

Biomarkers 0
Blood Glucose 0
Hormones 0
Adrenocorticotropic Hormone 9002-60-2
Glucagon 9007-92-5
Hydrocortisone WI4X0X7BPJ

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

641-655

Références

Unger RH, Cherrington AD (2012) Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 122(1):4–12. https://doi.org/10.1172/JCI60016
doi: 10.1172/JCI60016 pubmed: 22214853 pmcid: 22214853
Stanley S, Moheet A, Seaquist ER (2019) Central Mechanisms of Glucose Sensing and Counterregulation in Defense of Hypoglycemia. Endocr Rev 40(3):768–788. https://doi.org/10.1210/er.2018-00226
doi: 10.1210/er.2018-00226 pubmed: 30689785 pmcid: 6505456
Farngren J, Ahren B (2019) Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes. Metabolism 99:25–31. https://doi.org/10.1016/j.metabol.2019.06.016
doi: 10.1016/j.metabol.2019.06.016 pubmed: 31279738
Mitrakou A, Kelley D, Mokan M et al (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326(1):22–29. https://doi.org/10.1056/NEJM199201023260104
doi: 10.1056/NEJM199201023260104 pubmed: 1727062
Bagger JI, Knop FK, Lund A, Holst JJ, Vilsboll T (2014) Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals. Diabetologia 57(8):1720–1725. https://doi.org/10.1007/s00125-014-3264-2
doi: 10.1007/s00125-014-3264-2 pubmed: 24879388
Ichikawa R, Takano K, Fujimoto K et al (2019) Basal glucagon hypersecretion and response to oral glucose load in prediabetes and mild type 2 diabetes. Endocr J 66(8):663–675. https://doi.org/10.1507/endocrj.EJ18-0372
Klement J, Kubera B, Eggeling J et al (2018) Effects of blood glucose on delay discounting, food intake and counterregulation in lean and obese men. Psychoneuroendocrinology 89:177–184. https://doi.org/10.1016/j.psyneuen.2018.01.014
doi: 10.1016/j.psyneuen.2018.01.014 pubmed: 29414030
Shamoon H, Friedman S, Canton C, Zacharowicz L, Hu M, Rossetti L (1994) Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus. J Clin Invest 93(6):2562–2571. https://doi.org/10.1172/JCI117267
doi: 10.1172/JCI117267 pubmed: 8200993 pmcid: 294484
Weaver JU, Kopelman PG, McLoughlin L, Forsling ML, Grossman A (1993) Hyperactivity of the hypothalamo-pituitary-adrenal axis in obesity: a study of ACTH, AVP, beta-lipotrophin and cortisol responses to insulin-induced hypoglycaemia. Clin Endocrinol 39(3):345–350. https://doi.org/10.1111/j.1365-2265.1993.tb02375.x
doi: 10.1111/j.1365-2265.1993.tb02375.x
Lundqvist MH, Almby K, Abrahamsson N, Eriksson JW (2019) Is the Brain a Key Player in Glucose Regulation and Development of Type 2 Diabetes? Front Physiol 10:457. https://doi.org/10.3389/fphys.2019.00457
doi: 10.3389/fphys.2019.00457 pubmed: 31133864 pmcid: 6524713
Dunning BE, Gerich JE (2007) The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 28(3):253–283. https://doi.org/10.1210/er.2006-0026
doi: 10.1210/er.2006-0026 pubmed: 17409288
Coiro V, Passeri M, d’Amato L et al (1988) Glucagon response to insulin-induced hypoglycemia in obese men. Horm Metab Res 20(10):656–657. https://doi.org/10.1055/s-2007-1010910
doi: 10.1055/s-2007-1010910 pubmed: 3065200
Lassmann V, Cabrerizzo Garcia L, Vialettes B, Vague P (1985) Impaired pancreatic polypeptide response to insulin hypoglycemia in obese subjects. Horm Metab Res 17(12):663–666. https://doi.org/10.1055/s-2007-1013638
doi: 10.1055/s-2007-1013638 pubmed: 3002934
Bischof MG, Ludwig C, Hofer A et al (2000) Hormonal and metabolic counterregulation during and after high-dose insulin-induced hypoglycemia in diabetes mellitus type 2. Horm Metab Res 32(10):417–423. https://doi.org/10.1055/s-2007-978664
doi: 10.1055/s-2007-978664 pubmed: 11069207
Gylfe E (2016) Glucose control of glucagon secretion-‘There’s a brand-new gimmick every year’. Ups J Med Sci 121(2):120–132. https://doi.org/10.3109/03009734.2016.1154905
doi: 10.3109/03009734.2016.1154905 pubmed: 27044660 pmcid: 4900067
Abraham SB, Rubino D, Sinaii N, Ramsey S, Nieman LK (2013) Cortisol, obesity, and the metabolic syndrome: a cross-sectional study of obese subjects and review of the literature. Obesity (Silver Spring) 21(1):E105–E117. https://doi.org/10.1002/oby.20083
doi: 10.1002/oby.20083
Incollingo Rodriguez AC, Epel ES, White ML, Standen EC, Seckl JR, Tomiyama AJ (2015) Hypothalamic-pituitary-adrenal axis dysregulation and cortisol activity in obesity: A systematic review. Psychoneuroendocrinology 62:301–318. https://doi.org/10.1016/j.psyneuen.2015.08.014
doi: 10.1016/j.psyneuen.2015.08.014 pubmed: 26356039
Scacchi M, Pincelli AI, Cavagnini F (1999) Growth hormone in obesity. Int J Obes Relat Metab Disord 23(3):260–271. https://doi.org/10.1038/sj.ijo.0800807
doi: 10.1038/sj.ijo.0800807 pubmed: 10193871
Rasmussen MH (2010) Obesity, growth hormone and weight loss. Mol Cell Endocrinol 316(2):147–153. https://doi.org/10.1016/j.mce.2009.08.017
doi: 10.1016/j.mce.2009.08.017 pubmed: 19723558
Benichou T, Pereira B, Mermillod M et al (2018) Heart rate variability in type 2 diabetes mellitus: A systematic review and meta-analysis. PLoS One 13(4):e0195166. https://doi.org/10.1371/journal.pone.0195166
doi: 10.1371/journal.pone.0195166 pubmed: 29608603 pmcid: 5880391
Kim JA, Park YG, Cho KH et al (2005) Heart rate variability and obesity indices: emphasis on the response to noise and standing. J Am Board Fam Pract 18(2):97–103. https://doi.org/10.3122/jabfm.18.2.97
doi: 10.3122/jabfm.18.2.97 pubmed: 15798138
Saito I, Hitsumoto S, Maruyama K et al (2015) heart rate variability, insulin resistance, and insulin sensitivity in japanese adults: the toon health study. J Epidemiol 25(9):583–591. https://doi.org/10.2188/jea.JE20140254
doi: 10.2188/jea.JE20140254 pubmed: 26277879 pmcid: 4549610
Deem JD, Muta K, Scarlett JM, Morton GJ, Schwartz MW (2017) How should we think about the role of the brain in glucose homeostasis and diabetes? Diabetes 66(7):1758–1765. https://doi.org/10.2337/dbi16-0067
doi: 10.2337/dbi16-0067 pubmed: 28603139 pmcid: 5482090
Abrahamsson N, Borjesson JL, Sundbom M, Wiklund U, Karlsson FA, Eriksson JW (2016) Gastric Bypass Reduces Symptoms and Hormonal Responses in Hypoglycemia. Diabetes 65(9):2667–2675. https://doi.org/10.2337/db16-0341
doi: 10.2337/db16-0341 pubmed: 27313315
Guldstrand M, Ahren B, Wredling R, Backman L, Lins PE, Adamson U (2003) Alteration of the counterregulatory responses to insulin-induced hypoglycemia and of cognitive function after massive weight reduction in severely obese subjects. Metabolism 52(7):900–907. https://doi.org/10.1016/s0026-0495(03)00103-3
doi: 10.1016/s0026-0495(03)00103-3 pubmed: 12870168
Norjavaara E, Ericsson H, Sjoberg F et al (2012) Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males. J Clin Endocrinol Metab 97(9):3319–3325. https://doi.org/10.1210/jc.2012-1496
doi: 10.1210/jc.2012-1496 pubmed: 22723318
DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Phys 237(3):E214–E223. https://doi.org/10.1152/ajpendo.1979.237.3.E214
doi: 10.1152/ajpendo.1979.237.3.E214
Zhang Y, Chi J, Wang W et al (2015) Different effects of two dipeptidyl peptidase-4 inhibitors and glimepiride on beta-cell function in a newly designed two-step hyperglycemic clamp. J Diabetes 7(2):213–221. https://doi.org/10.1111/1753-0407.12175
doi: 10.1111/1753-0407.12175 pubmed: 24889731
Deary IJ, Hepburn DA, MacLeod KM, Frier BM (1993) Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis. Diabetologia 36(8):771–777. https://doi.org/10.1007/BF00401150
doi: 10.1007/BF00401150 pubmed: 8405746
McAulay V, Deary IJ, Ferguson SC, Frier BM (2001) Acute hypoglycemia in humans causes attentional dysfunction while nonverbal intelligence is preserved. Diabetes Care 24(10):1745–1750. https://doi.org/10.2337/diacare.24.10.1745
doi: 10.2337/diacare.24.10.1745 pubmed: 11574436
Berntson GG, Bigger JT Jr, Eckberg DL et al (1997) Heart rate variability: origins, methods, and interpretive caveats. Psychophysiology 34(6):623–648. https://doi.org/10.1111/j.1469-8986.1997.tb02140.x
doi: 10.1111/j.1469-8986.1997.tb02140.x pubmed: 9401419
Wewer Albrechtsen NJ, Hartmann B, Veedfald S et al (2014) Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia 57(9):1919–1926. https://doi.org/10.1007/s00125-014-3283-z
doi: 10.1007/s00125-014-3283-z pubmed: 24891019
Lindmark S, Lonn L, Wiklund U, Tufvesson M, Olsson T, Eriksson JW (2005) Dysregulation of the autonomic nervous system can be a link between visceral adiposity and insulin resistance. Obes Res 13(4):717–728. https://doi.org/10.1038/oby.2005.81
doi: 10.1038/oby.2005.81 pubmed: 15897481
Schmid SM, Hallschmid M, Jauch-Chara K, Bandorf N, Born J, Schultes B (2007) Sleep loss alters basal metabolic hormone secretion and modulates the dynamic counterregulatory response to hypoglycemia. J Clin Endocrinol Metab 92(8):3044–3051. https://doi.org/10.1210/jc.2006-2788
doi: 10.1210/jc.2006-2788 pubmed: 17519315
Ahren B, Schweizer A, Dejager S et al (2009) Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 94(4):1236–1243. https://doi.org/10.1210/jc.2008-2152
doi: 10.1210/jc.2008-2152 pubmed: 19174497
Tomlinson JW, Finney J, Gay C, Hughes BA, Hughes SV, Stewart PM (2008) Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. Diabetes 57(10):2652–2660. https://doi.org/10.2337/db08-0495
doi: 10.2337/db08-0495 pubmed: 18633104 pmcid: 2551674
Svensson MK, Lindmark S, Wiklund U et al (2016) Alterations in heart rate variability during everyday life are linked to insulin resistance. A role of dominating sympathetic over parasympathetic nerve activity? Cardiovasc Diabetol 15:91. https://doi.org/10.1186/s12933-016-0411-8
doi: 10.1186/s12933-016-0411-8 pubmed: 27352833 pmcid: 4924321
Perini R, Veicsteinas A (2003) Heart rate variability and autonomic activity at rest and during exercise in various physiological conditions. Eur J Appl Physiol 90(3–4):317–325. https://doi.org/10.1007/s00421-003-0953-9
doi: 10.1007/s00421-003-0953-9 pubmed: 13680241
Rodriguez-Diaz R, Caicedo A (2014) Neural control of the endocrine pancreas. Best Pract Res Clin Endocrinol Metab 28(5):745–756. https://doi.org/10.1016/j.beem.2014.05.002
doi: 10.1016/j.beem.2014.05.002 pubmed: 25256769
Taborsky GJ Jr, Mundinger TO (2012) Minireview: The role of the autonomic nervous system in mediating the glucagon response to hypoglycemia. Endocrinology 153(3):1055–1062. https://doi.org/10.1210/en.2011-2040
doi: 10.1210/en.2011-2040 pubmed: 22315452 pmcid: 3384078
Yi CX, la Fleur SE, Fliers E, Kalsbeek A (2010) The role of the autonomic nervous liver innervation in the control of energy metabolism. Biochim Biophys Acta 1802(4):416–431. https://doi.org/10.1016/j.bbadis.2010.01.006
doi: 10.1016/j.bbadis.2010.01.006 pubmed: 20060897
Svensson MK, Jansson PA, Persson AL, Sjostrand M, Eriksson JW (2011) Atropine improves insulin sensitivity in both lean and abdominally obese subjects. J Clin Endocrinol Metab 96(11):E1843–E1847. https://doi.org/10.1210/jc.2011-0669
doi: 10.1210/jc.2011-0669 pubmed: 21865364
Solomon TP, Knudsen SH, Karstoft K, Winding K, Holst JJ, Pedersen BK (2012) Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity. J Clin Endocrinol Metab 97(12):4682–4691. https://doi.org/10.1210/jc.2012-2097
doi: 10.1210/jc.2012-2097 pubmed: 23043193
Vilsboll T, Krarup T, Madsbad S, Holst JJ (2002) Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45(8):1111–1119. https://doi.org/10.1007/s00125-002-0878-6
doi: 10.1007/s00125-002-0878-6 pubmed: 12189441
Bonora E, Moghetti P, Cacciatori V et al (1990) Plasma concentrations of glucagon during hyperglycemic clamp with or without somatostatin infusion in obese subjects. Acta Diabetol Lat 27(4):309–314. https://doi.org/10.1007/bf02580935
doi: 10.1007/bf02580935 pubmed: 1982386
Follenius M, Brandenberger G, Hietter B (1982) Diurnal cortisol peaks and their relationships to meals. J Clin Endocrinol Metab 55(4):757–761. https://doi.org/10.1210/jcem-55-4-757
doi: 10.1210/jcem-55-4-757 pubmed: 7202017
Reynolds RM, Walker BR, Syddall HE, Whorwood CB, Wood PJ, Phillips DI (2001) Elevated plasma cortisol in glucose-intolerant men: differences in responses to glucose and habituation to venepuncture. J Clin Endocrinol Metab 86(3):1149–1153. https://doi.org/10.1210/jcem.86.3.7300
doi: 10.1210/jcem.86.3.7300 pubmed: 11238500
Bonora E, Moghetti P, Zenere M et al (1990) Plasma concentrations of growth hormone during hyperglycemic clamp with or without somatostatin infusion in obese subjects. J Clin Endocrinol Metab 70(6):1732–1734. https://doi.org/10.1210/jcem-70-6-1732
doi: 10.1210/jcem-70-6-1732 pubmed: 1971827

Auteurs

Martin H Lundqvist (MH)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Kristina Almby (K)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Urban Wiklund (U)

Department of Radiation Sciences, Biomedical Engineering, Umeå University, Umeå, Sweden.

Niclas Abrahamsson (N)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Prasad G Kamble (PG)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Maria J Pereira (MJ)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Jan W Eriksson (JW)

Department of Medical Sciences, Uppsala University, Uppsala, Sweden. jan.eriksson@medsci.uu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH